The efficacy of low-dose aspirin in pregnancy among women in malaria-endemic countries

Table 4 Hemoglobin level, by malaria infection and aspirin exposure

Hemoglobin cut-point	Overall		Malaria Negative		Malaria positive
Hemoglobin cut-point	N (w/ and w/o outcome)	PR (95% CI)	N (w/ and w/o outcome)	PR (95% CI)	N (w/ and w/o outcome)	PR (95% CI)
Hemoglobin ≤ 8 g/dL
Aspirin	11/618	0·91 (0·04, 2·04)	3/376	0·58 (0·14, 2·43)	8/242	1·16 (0·43, 3·14)
Placebo	12/610		5/364		7/246
Hemoglobin ≤ 9 g/dL
Aspirin	43/586	1·06 (0·70, 1·58)	10/369	0·57 (0·27, 1·23)	33/217	1·34 (0·82, 2·18)
Placebo	42/580		17/352		25/228
Hemoglobin ≤ 10 g/dL
Aspirin	122/507	1·01 (0·80, 1·26)	49/330	1·04 (0·71, 1·51)	73/177	1·00 (0·76, 1·31)
Placebo	120/502		46/323		74/179
Hemoglobin ≤ 11 g/dL
Aspirin	266/363	1·03 (0·90, 1·17)	128/251	1·07 (0·87, 1·31)	138/112	1·00 (0·86, 1·18)
Placebo	256/366		117/252		139/114

Note: Hemoglobin measured between 26–30 weeks. Malaria in early pregnancy measured between 6–13 6/7 weeks gestation

ISSN: 1471-2393